Protein-based COVID-19 Vaccine Candidate Switches Adjuvant Partner

In COVID-19, Latest News by Precision Vaccinations

Clover Biopharmaceuticals and Dynavax Technologies Corporation announced their plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted, with CpG 1018 plus alum in the first half of 2021.
In a press release on February 1, 2021, the companies stated an interim analysis for vaccine efficacy may become available in the middle of 2021.
Clover stated it expects to produce hundreds of millions of vaccine doses in 2021 and up to 1 billion vaccine doses in peak annual production as required by global demand.

Read More